Longitudinal CSF biomarker trajectories from middle age to late adulthood

Journal article

C. Pettigrew, Anja Soldan, Jiangxia Wang, Mei-Cheng Wang, Barry D. Greenberg, M. Albert, A. Moghekar
Alzheimer's & Dementia, 2022

Semantic Scholar DOI

Cite

APA Click to copy
Pettigrew, C., Soldan, A., Wang, J., Wang, M.-C., Greenberg, B. D., Albert, M., & Moghekar, A. (2022). Longitudinal CSF biomarker trajectories from middle age to late adulthood. Alzheimer's &Amp;Amp; Dementia.

Chicago/Turabian Click to copy
Pettigrew, C., Anja Soldan, Jiangxia Wang, Mei-Cheng Wang, Barry D. Greenberg, M. Albert, and A. Moghekar. “Longitudinal CSF Biomarker Trajectories from Middle Age to Late Adulthood.” Alzheimer's & Dementia (2022).

MLA Click to copy
Pettigrew, C., et al. “Longitudinal CSF Biomarker Trajectories from Middle Age to Late Adulthood.” Alzheimer's &Amp;Amp; Dementia, 2022.

BibTeX Click to copy

@article{c2022a,
  title = {Longitudinal CSF biomarker trajectories from middle age to late adulthood},
  year = {2022},
  journal = {Alzheimer's &amp; Dementia},
  author = {Pettigrew, C. and Soldan, Anja and Wang, Jiangxia and Wang, Mei-Cheng and Greenberg, Barry D. and Albert, M. and Moghekar, A.}
}

Abstract

Current cerebrospinal fluid (CSF) biomarker data of preclinical AD are based largely on cross‐sectional studies across the disease spectrum and short‐term longitudinal studies, with most studies conducted among older adults. However, neuropathological studies indicate that AD pathology is present in midlife. To better understand within‐person biomarker trajectories, we examined longitudinal changes in CSF biomarkers, potential modifiers (e.g., demographics, APOE4 genotype), and changes with respect to MCI symptom onset among participants who were primarily middle‐aged and cognitively normal at baseline, and have on average 10.7y of follow‐up (max 23y).